Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:FLWRTSE:INCVE:NDVANASDAQ:VIRNYSEAMERICAN:ZOM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLWRFlowrC$0.03C$0.02C$0.02▼C$0.11C$10.66MN/A302,866 shs29,006 shsINInMed PharmaceuticalsC$4.19C$3.35▼C$13.86C$33.73MN/A29,552 shs17,035 shsNDVAIndivaC$0.07+16.7%C$0.08C$0.02▼C$0.13C$13.67M1.1198,881 shs66,695 shsVIRVir Biotechnology$8.04-1.1%$10.03$7.72▼$27.48$1.08B0.411.04 million shs767,449 shsZOMZomedica$0.13-0.8%$0.00$0.12▼$0.25$127.59M15.21 million shs2.53 million shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLWRFlowr0.00%0.00%0.00%0.00%0.00%INInMed Pharmaceuticals0.00%0.00%0.00%0.00%0.00%NDVAIndiva+16.67%+7.69%-12.50%-26.32%+7.69%VIRVir Biotechnology+0.37%-2.75%-19.10%-15.58%-67.99%ZOMZomedica0.00%0.00%+1.67%+4.23%-33.73%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFLWRFlowrN/AN/AN/AN/AN/AN/AN/AN/AINInMed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANDVAIndivaN/AN/AN/AN/AN/AN/AN/AN/AVIRVir Biotechnology2.7464 of 5 stars3.33.00.00.01.43.31.3ZOMZomedicaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLWRFlowrN/AN/AN/AN/AINInMed PharmaceuticalsN/AN/AN/AN/ANDVAIndiva3.00BuyC$0.15114.29% UpsideVIRVir Biotechnology2.57Moderate Buy$34.38327.55% UpsideZOMZomedicaN/AN/AN/AN/ACurrent Analyst RatingsLatest FLWR, VIR, ZOM, IN, and NDVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.002/23/2024VIRVir BiotechnologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$9.00 ➝ $10.002/14/2024VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$85.00 ➝ $110.001/29/2024VIRVir BiotechnologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$23.00 ➝ $9.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLWRFlowrC$12.92M0.83C$0.00 per share8.33C$0.00 per share-25.00INInMed PharmaceuticalsC$574.68K0.00N/A10.40C$0.76 per share0.00NDVAIndivaC$36.01M0.38C$0.01 per share5.20N/A∞VIRVir Biotechnology$86.18M12.55N/AN/A$11.82 per share0.68ZOMZomedica$25.19M5.07N/AN/A$0.24 per share0.54Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLWRFlowrN/A-C$0.21N/A∞N/AN/AN/AN/AN/AINInMed PharmaceuticalsN/A-C$1.51N/AN/AN/AN/AN/AN/AN/ANDVAIndiva-C$6.94M-C$0.05N/A∞N/A-19.27%-288.64%-6.91%5/14/2024 (Estimated)VIRVir Biotechnology-$615.06M-$4.59N/AN/AN/A-713.69%-34.92%-27.73%5/2/2024 (Confirmed)ZOMZomedica-$34.53M-$0.04N/A∞N/A-137.10%-8.13%-7.68%5/9/2024 (Estimated)Latest FLWR, VIR, ZOM, IN, and NDVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/2/2024N/AVIRVir Biotechnology-$0.99N/A+$0.99N/AN/AN/A 4/1/2024Q4 2023ZOMZomedicaN/A-$0.01-$0.01N/A$7.00 million$7.34 million 2/22/2024Q4 2023VIRVir Biotechnology-$1.14-$0.86+$0.28-$0.86$11.18 million$16.80 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFLWRFlowrN/AN/AN/AN/AN/AINInMed PharmaceuticalsN/AN/AN/AN/AN/ANDVAIndivaN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/AZOMZomedicaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLWRFlowr71.271.130.15INInMed Pharmaceuticals8.482.131.45NDVAIndiva5,899.220.850.52VIRVir BiotechnologyN/A9.059.05ZOMZomedicaN/A11.0610.49OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLWRFlowrN/AINInMed PharmaceuticalsN/ANDVAIndiva0.33%VIRVir Biotechnology65.32%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipFLWRFlowrN/AINInMed PharmaceuticalsN/ANDVAIndiva36.29%VIRVir Biotechnology18.10%ZOMZomedica4.18%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableFLWRFlowr186426.47 millionN/ANot OptionableINInMed Pharmaceuticals128.05 millionN/ANot OptionableNDVAIndiva147,000195.30 millionN/ANot OptionableVIRVir Biotechnology587134.50 million110.16 millionOptionableZOMZomedica144979.95 million938.99 millionNot OptionableFLWR, VIR, ZOM, IN, and NDVA HeadlinesSourceHeadlineWhat’s Happening at the Defender Kentucky Three Day Eventeventingnation.com - April 21 at 12:53 PMZomedica (NYSEAMERICAN:ZOM) Stock Price Down 4.3%americanbankingnews.com - April 21 at 6:12 AMZomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024accesswire.com - April 9 at 6:30 AMZomedica Corp. (AMEX:ZOM) Q4 2023 Earnings Call Transcriptmsn.com - April 2 at 4:06 PMQ4 2023 Zomedica Corp Earnings Callfinance.yahoo.com - April 2 at 8:30 AMZOM Stock Earnings: Zomedica Beats Revenue for Q4 2023investorplace.com - April 1 at 9:06 PMZomedica reports Q4 resultsmsn.com - April 1 at 5:27 PMZomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidityaccesswire.com - April 1 at 4:05 PMThe Next Millionaire-Makers: 3 Penny Stocks With Massive Upside Potentialinvestorplace.com - April 1 at 3:12 PMZomedica to Report Fourth Quarter and Full Year 20…pharmiweb.com - March 20 at 9:17 AMZomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ETaccesswire.com - March 20 at 6:30 AMZomedica Pharmaceuticals Corp (ZOM)investing.com - March 15 at 7:52 AMZomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platformaccesswire.com - March 14 at 6:30 AMZomedica Provides NYSE American Listing Updateaccesswire.com - March 13 at 4:45 PMSidoti & Company, LLC: Sidoti Events, LLC's Virtual March Small-Cap Conferencefinanznachrichten.de - March 12 at 11:26 AMZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferencesfinanznachrichten.de - March 12 at 8:22 AMZomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferencesaccesswire.com - March 12 at 6:30 AMZomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogsaccesswire.com - March 7 at 6:30 AMZomedica to Present at the Sidoti Small Cap Conference March 14, 2024accesswire.com - March 5 at 6:30 AMZomedica Pharmaceuticals Corp. (ZOM)uk.finance.yahoo.com - March 1 at 2:46 PMZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferencesfinanznachrichten.de - February 8 at 9:14 AMZomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferencesfinance.yahoo.com - February 8 at 9:14 AMZomedica Corp.: Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidationfinanznachrichten.de - February 6 at 5:00 PMLeading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)finance.yahoo.com - February 6 at 5:00 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeCharles Schwab Fortifies its Uptrend on EPS Beat April 23, 2024 10:15 AMView Charles Schwab Fortifies its Uptrend on EPS Beat Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better BetApril 2, 2024 9:15 AMView Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better BetAll Headlines Company DescriptionsFlowrCVE:FLWRThe Flowr Corporation cultivates, produces, and sells cannabis in Canada. The company offers dried flowers and pre-rolls. It also has operations in Canada, Portugal, and the European Union. The company was incorporated in 2016 and is headquartered in Toronto, Canada.InMed PharmaceuticalsTSE:INInMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.IndivaCVE:NDVAIndiva Limited engages in the production, processing, and sale of cannabis and cannabis related products in Canada. It offers pre-rolls, flower, capsules, and edible and extract products under the INDIVA, Indiva Life, and Artisan Batch brands. The company produces and distributes the Bhang Chocolate, Wana Sour Gummies, Jewels Chewable Tarts, Grön edibles, and Dime Industries vape products through license agreements and partnerships. Indiva Limited is based in Ottawa, Canada.Vir BiotechnologyNASDAQ:VIRVir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.ZomedicaNYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.